Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04928222 · ClinicalTrials.gov registry record · Phase 1
Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)
A Phase 1 study of Basal Cell Carcinoma, sponsored by SkinJect.
- Active
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT04928222 is a Phase 1 study of Basal Cell Carcinoma that is active but no longer recruiting, run by SkinJect. The registered enrollment target is 25 participants, below the 103-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (76% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04928222, a Phase 1 study of Basal Cell Carcinoma, is active but no longer recruiting, sponsored by SkinJect.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
Part I is designed as a study of P-MNA application in healthy human volunteers. The goal of Part I is to determine several factors possibly affecting the rate and extent of microneedle array dissolution, such as anatomic location; age; duration of array exposure to the skin; and the criticality of proper array application to the skin. Part II will be a randomized study in which doxorubicin-containing arrays will be applied to subjects demonstrated by biopsy to have basal cell cancer. A subject will be randomized to one of four dose groups: placebo microneedle array and 50 µg, 100 µg, and 200 µg doses of doxorubicin in a tip-loaded, dissolvable microneedle arrays (D-MNA).
Conditions Studied
Interventions
- COMBINATION_PRODUCT Doxorubicin-containing MNA
- DRUG Placebo-containing MNA
Study Locations (2)
Florida
- Beer Dermatology - West Palm Beach
New York
- New York and Presbyterian Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-09-24 |
| Est. Completion | 2024-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04928222
The ClinicalTrials.gov registry entry for NCT04928222 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (76% lower). The listed sponsor is SkinJect, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Basal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Doxorubicin-containing MNA is the first listed.
NCT04928222 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, New York.
Frequently Asked Questions
What is clinical trial NCT04928222 about?
NCT04928222 is a clinical study titled "Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)". Part I is designed as a study of P-MNA application in healthy human volunteers. The goal of Part I is to determine several factors possibly affecting the rate and extent of microneedle array dissolution, such as anatomic location; age; duration of array exposure to the skin; and the criticality of p...
What is the current status of trial NCT04928222?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2021-09-24. Estimated completion is 2024-06-30.
What conditions does trial NCT04928222 study?
This clinical trial studies the following conditions: Basal Cell Carcinoma.
What interventions are being tested in trial NCT04928222?
The interventions under investigation include: Doxorubicin-containing MNA (COMBINATION_PRODUCT), Placebo-containing MNA (DRUG).
Who is sponsoring clinical trial NCT04928222?
This trial is sponsored by SkinJect, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04928222 being conducted?
This trial has 2 study locations across Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Basal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
RECRUITING · Phase 1
-
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
RECRUITING · Phase 2
-
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
RECRUITING · Phase 2
-
Investigation of Standard Excision Surgical Margins Using Two Photon Fluorescence Microscopy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.